NCT04264858

Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients

An Exploratory Clinical Study on the Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured 2019-nCoV Pneumonia Patients

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The new coronavirus pneumonia is an acute infectious pneumonia. The pathogen is a previously unknown new coronavirus, namely 2019 new coronavirus (2019 novel coronavirus, 2019 nCoV). However, there is no specific anti-viral drug. It has been found that the specific antibodies against virus antigen are produced after these patients were cured, which could block the infection of 2019 nCoV on the host cells. At present, immunoadsorption is the most direct, rapid and effective method to separate immunoglobulin from the cured patients. Therefore, the study aims to prepare the immunoglobulin from 2019-ncov pneumonia cured patients, evaluate the efficacy and safety of the immunoglobulin in 2019-ncov pneumonia cured patients on the treatment of acute severe 2019-ncov pneumonia, and provide a new strategy for the treatment of 2019-ncov pneumonia.

Conditions

• 2019-nCoV
• Immunoglobulin of Cured Patients

Interventions

Type	Name	Description
DRUG	Immunoglobulin of cured patients	0.2g/kg, ivdrip, once a day, for 3 days
DRUG	γ-Globulin	0.2g/kg, ivdrip, once a day, for 3 days

Timeline

• Start date: 2020-03-17
• Primary completion: 2020-04-30
• Completion: 2020-05-31
• First posted: 2020-02-11
• Last updated: 2020-03-17

Locations

1 site across 1 country: China